EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs

Zongyu Cai, Yaru Qiao, Qimuge Wuri, Ke Zhang, Xueli Qu, Shiqi Zhang, Hui Wu, Jiaxin Wu, Chu Wang, Xianghui Yu, Wei Kong, Haihong Zhang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.112956 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Zongyu Cai und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Vaccines, DNA, Dendritic Cells, Programmed Cell Death 1 Receptor, Cancer Vaccines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

DNA vaccines are prospective for their efficient manufacturing process, but their immunogenicity is limited as they cannot efficiently induce CD8+ T cell responses. A promising approach is to induce cross-presentation by targeting antigens to DCs. Flt3L can expand the number of type 1 conventional DCs and thereby improve cross-presentation. In this study, we first constructed a DNA vaccine expressing soluble PD1 and found that the therapeutic effect of targeting DCs with only the sPD1 vaccine was limited. When combined the vaccine with Flt3L, the anti-tumor effect was significantly enhanced. Considering the complexity of tumors and that a single method may not be able to activate a large number of effective CD8+ T cells, we combined different drugs and the vaccine with Flt3L based on the characteristics of different tumors. In 4T1 model, we reduced Tregs through cyclophosphamide. In Panc02 model, we increased activated DCs by using aCD40. Both strategies triggered strong CD8+ T cell responses and significantly improved the therapeutic effect. Our study provides important support for the clinical exploration of DC-targeted DNA vaccines in combination with Flt3L.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vaccines, DNADendritic CellsProgrammed Cell Death 1 ReceptorCancer VaccinesCD8-Positive T-LymphocytesMembrane ProteinsMice, Inbred BALB CAnimalsFemaleMiceCell Line, TumorHumansMice, Inbred C57BL

Stichwörter der Autor:innen

Cross-presentationDNA vaccineFlt3LImmunotherapysPD1

Substanzen

flt3 ligand proteinVaccines, DNAProgrammed Cell Death 1 ReceptorCancer VaccinesMembrane ProteinsPdcd1 protein, mouse

Autor:innen und Institutionen

  • National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China.
  • National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China; Key Laboratory for Molecular Enzymology and Engineering, the Ministry of Education, School of Life Sciences,…
  • National Engineering Laboratory for AIDS Vaccine, School of Life Science, Jilin University, Changchun, China. Electronic address: zhanghh@jlu.edu.cn.

Zitieren

APA

Cai, Z., Qiao, Y., Wuri, Q., Zhang, K., Qu, X., Zhang, S., Wu, H., Wu, J., Wang, C., Yu, X., Kong, W., & Zhang, H. (2024). Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112956

Vancouver

Cai Z, Qiao Y, Wuri Q, Zhang K, Qu X, Zhang S, et al. Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112956

BibTeX
@article{Cai2024,
  author = {Cai, Zongyu and Qiao, Yaru and Wuri, Qimuge and Zhang, Ke and Qu, Xueli and Zhang, Shiqi and Wu, Hui and Wu, Jiaxin and Wang, Chu and Yu, Xianghui and Kong, Wei and Zhang, Haihong},
  title = {Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.112956}
}
Kostenlos starten →